Affiliation:
1. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee
Abstract
This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.
Publisher
American Medical Association (AMA)
Reference6 articles.
1. Bispecifics, trispecifics, and other novel immune treatments in myeloma.;Lancman;Hematology Am Soc Hematol Educ Program,2020
2. Teclistamab, a B-cell maturation antigen?×?CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.;Usmani;Lancet,2021
3. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.;Kambhampati;Blood Adv,2022
4. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.;Mohan;Blood Adv,2022
5. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.;Wang;Blood Adv,2021
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献